Partnering with Novo Nordisk:
What is in it for you?
At Novo Nordisk, we know the importance that research partnerships play in securing successful pipeline development. Here is why we think you should consider partnering with us:
We have a clear strategy in our focused disease areas
We believe in open and honest collaborations based on long-term commitment and mutual interest that are mindful of financial, environmental and societal considerations
- We offer world-class protein and peptide technology and development expertise
- We are a global research and development organisation with a strong history of collaborating with healtcare professionals and clinical trial centres around the world to develop proteins from molecule to market
Partnering and collaboration
Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk, discusses the importance of scientific partnerships and collaborations to fulfil Novo Nordisk's mission to develop innovative therapeutic proteins for chronic illnesses.
Proteins are our core competency
For almost a century we have discovered, developed and marketed protein-based therapeutics. We continue to leverage our leading expertise in all aspects of designing, expressing, engineering, formulating and delivering proteins to develop new and innovative therapies for people with chronic diseases like diabetes, haemophilia and autoimmune inflammatory disorders.
We have global reach
Novo Nordisk is a global organisation headquartered in Denmark. We have long-standing professional relationships with key opinion leaders and decision-makers in our main disease areas around the world and we work closely with them to develop, execute and communicate the clinical development of our products.
We conduct world-class research in target and drug discovery, as well as protein engineering at our research and development sites around the world:
- Sites, Denmark
- Beijing, China
- Seattle, USA
- Bangalore, India